Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective
| Autor: | Valentín Garcia-Gutiérrez, Andrija Bogdanovic, Felice Bombaci, Jelena Čugurović, Giuseppe Saglio, Jan de Jong, Šarūnas Narbutas, Peter E. Westerweel, Daniela Zackova, Antonio Almeida, Nigel B. Deekes, Giora Sharf |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.drug_class Decision Making Treatment goals Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine Patient Education as Topic Leukemia Myelogenous Chronic BCR-ABL Positive medicine Humans In patient Intensive care medicine Protein Kinase Inhibitors Physician-Patient Relations business.industry Remission Induction Myeloid leukemia Hematology Protein-Tyrosine Kinases Response to treatment 3. Good health Discontinuation Survival Rate Treatment Outcome Withholding Treatment Oncology 030220 oncology & carcinogenesis Quality of Life Neoplasm Recurrence Local Withdrawal syndrome Topic areas business 030215 immunology |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 18:375-379 |
| ISSN: | 2152-2650 |
| DOI: | 10.1016/j.clml.2018.04.005 |
| Popis: | Treatment-free remission (TFR) after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal for patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. Although guidance is now available, patients' questions regarding this progressive concept have yet to be addressed. The overall aim of this European Steering Group is a patient-centered approach that educates patients on their treatment options, including TFR, facilitates better patient-physician relationships, and meets patients' emotional and psychological needs. The present report outlines 5 key topic areas on discontinuing tyrosine kinase therapy and the implications of TFR for patient-physician consideration: what TFR is; when TFR is appropriate; which patients might and might not be eligible for TFR; and patients' considerations for discontinuing therapy, such as tyrosine kinase withdrawal syndrome, potential psychological implications, molecular recurrence, and repeat treatment. This Steering Group advocates that patients with chronic myeloid leukemia should have access to high-quality, frequent molecular monitoring and be treated in a specialist center with appropriate medical and psychological support. As patient concerns with attempting TFR become forefront in patient-physician discussions, a greater number of eligible patients might be willing to discontinue therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect